

**21<sup>st</sup> ANNUAL  
BSMO MEETING  
2019**



**Programme**

**Friday 22 and Saturday 23 February 2019**

**Palais des Congrès, Liège**

**[WWW.BSMO.BE](http://WWW.BSMO.BE)**

**10:00 General Assembly**

**10:30 Registration & coffee**

**11:00-13:00 Breast Cancer Task Force**

*chairs: Hans Wildiers & Evandro de Azambuja*

11:00 Clinical management of first line triple negative breast cancer (cases RFS  
 <math>\leq 1y, RFS > 1y</math>)  
*Michail Ignatiadis, Institut Jules Bordet*

11:30 Clinical management of first line triple negative breast cancer with BRCA  
 mutation  
*Jacques De Grève, UZ Brussel*

12:00 Treatment algorithm ER positive HER2 negative advanced breast cancer  
*Guy Jerusalem, CHU de Liège*

12:30 Academic clinical trials in Belgium: overview and brainstorm session  
 [closed session, **access only for BSMO members**]

**13:00 Sandwich lunch**

**14:00-18:00 General Session**

*chairs: Wim Demey & Jolanda Verheezzen*

14:00 Practice changing topics in breast cancer  
*Francois Duhoux, UC Louvain*

14:30 Practice changing topics in Sarcoma  
*Christine Gennigens, CHU de Liège*

15:00 Topics in lung cancer  
*Lore Decoster, UZ Brussel*

**15:30 Coffee & tea break**

**15:50 Pfizer award**

IREN : A multilingual decision aid to support cancer patients' decisions about  
 clinical trial participation  
*Patrick Miqueu, Institut Jules Bordet*

**16:00 Continuation General Session**

*chairs: Joelle Collignon & Sylvie Rottey*

16:00 Topics in gastrointestinal NEN (neuroendocrine neoplasms)  
*Karen Geboes, UZ Gent*

16:30 Tissue agnostic oncology  
*Hans Prenen, UZ Antwerpen*

17:00 Immunotherapy induced arthritis  
*Laurent de Bellefon, UC Louvain*

17:30 Update on ovarian cancer  
*Peter Vuylsteke, CHU UCL Namur*

18:00 Summary & closing

**19:00 Aperitif, visit to museum and dinner at Museum la Boverie (5 minutes walk)**

- 08:45 Registration & coffee**
- 09:15 Introduction  
*Jacques De Grève, BSMO President*
- 09:45 *Translational research 2018*  
*Luc Dirix, Iridum Kankernetwerk*
- 10:15 Paper of the Year**  
Identification of the tumour transition states occurring during  
*[EMT. Nature. 2018 Apr;556(7702):463-468]*  
*Cédric Blanpain, ULB Brussel*
- 10:45 Coffee break and poster session**
- 11:15 - 12:45 Proffered papers by junior members**  
*Chair: Peter Vuylsteke, CHU UCL Namur*
- 11.15 **0.01** Clinical outcome and prognostic factors in oligometastatic breast cancer  
*Tatjana Geukens, UZ Leuven*
- 11.25 **0.02** Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy  
*Cynthia D'Hondt, UZ Brussel*
- 11.35 **0.03** Ethnic paradigm in prostate cancer – does it really matter?  
*Fadi Dalati, CHU Saint Pierre*
- 11.45 **0.04** The spatial localization of immune cells predicts prognosis and response to therapy in inflammatory breast cancer  
*Christophe Van Berckelaer, UZ Antwerpen*
- 11.55 **0.05** The role of follicular helper CD4 T cells in breast cancer anti-tumoral immune response  
*Mireille diane Langouo Fontsa, Institut Jules Bordet*
- 12.05 **0.06** CTCs in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-directed therapy  
*Elisabeth De Meue, Sint Augustinus*
- 12.15 **0.07** Real-life value of follow-up FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemoradiation (CRT) or (chemo)radiation (C[RT]) preceded by induction chemotherapy (IC)  
*Bert Van Den Heuvel, UZ Antwerpen*
- 12.25 **0.08** Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: a retrospective analysis  
*Tim Wessels, UZ Leuven*
- 12.35 Voting best oral presentation
- 12:45 - 13:15 Heuson Lecture:**  
Lessons learned after two decades of translational research in early breast cancer trials  
*Martine Piccart, Institut Jules Bordet*
- 13:15 Awards**
- 13:30 Sandwich lunch**

### P01 Subgroup analysis of rucaparib in platinum-sensitive, recurrent ovarian carcinoma: effect of prior chemotherapy regimens in ARIEL3

*Luc Dirix<sup>1</sup>, Ignace Vergote<sup>2</sup>, Hannelore Denys<sup>3</sup>, Amit M. Oza<sup>4</sup>, Domenica Lorusso<sup>5</sup>, Carol Aghajanian<sup>6</sup>, Ana Oaknin<sup>7</sup>, Andrew Dean<sup>8</sup>, Nicoletta Colombo<sup>9</sup>, Johanne I. Weberpals<sup>10</sup>, Andrew R. Clamp<sup>11</sup>, Giovanni Scambia<sup>2</sup>, Alexandra Leary<sup>12</sup>, Robert W. Holloway<sup>13</sup>, Margarita Amenedo Gancedo<sup>14</sup>, Peter C. Fong<sup>15</sup>, Jeffrey C. Goh<sup>16</sup>, David M. O'Malley<sup>17</sup>, Susana Banerjee<sup>18</sup>, Sandra Goble<sup>19</sup>, Terri Cameron<sup>20</sup>, Robert L. Coleman<sup>21</sup>, Jonathan A. Ledermann<sup>22</sup>*

<sup>1</sup>AZ Sint Augustinus, WILRIJK, Belgium

<sup>2</sup>Universitair Ziekenhuis Leuven, LEUVEN, Belgium

<sup>3</sup>Universitair Ziekenhuis Gent, GENT, Belgium

<sup>4</sup>Princess Margaret Cancer Centre, University Health Network, TORONTO, Canada

<sup>5</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS and MITO, ROME, Italy

<sup>6</sup>Memorial Sloan Kettering Cancer Center, NEW YORK, USA

<sup>7</sup>Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), BARCELONA, Spain

<sup>8</sup>St John of God Subiaco Hospital, SUBIACO, Australia

<sup>9</sup>European Institute of Oncology and University of Milan-Bicocca, MILAN, Italy

<sup>10</sup>Ottawa Hospital Research Institute, OTTAWA, Canada

<sup>11</sup>The Christie NHS Foundation Trust and University of Manchester, MANCHESTER, United Kingdom

<sup>12</sup>Gustave Roussy Cancer Center, INSERM U981, and GINECO, VILLEJUIF, France

<sup>13</sup>Florida Hospital Cancer Institute, ORLANDO, USA

<sup>14</sup>Oncology Center of Galicia, LA CORUÑA, Spain

<sup>15</sup>Auckland City Hospital, GRAFTON, Australia

<sup>16</sup>Royal Brisbane and Women's Hospital and University of Queensland, HERSTON, Australia

<sup>17</sup>The Ohio State University, James Cancer Center, COLUMBUS, USA

<sup>18</sup>The Royal Marsden NHS Foundation Trust, LONDON, United Kingdom

<sup>19</sup>Clovis Oncology, Inc., BOULDER, USA

<sup>20</sup>Clinical Science, Clovis Oncology, Inc., Boulder/US

<sup>21</sup>The University of Texas MD Anderson Cancer Center, HOUSTON, USA

<sup>22</sup>UCL Cancer Institute and UCL Hospitals, LONDON, United Kingdom

### P02 OPINIONS OF LUNG CANCER PATIENTS ON TOBACCO ADVERTISING AND SMOKING IN PUBLIC PLACES

*Garry Mahon<sup>1</sup>, Mario Dicato<sup>2</sup>*

<sup>1</sup>Foundation for Research on Cancer and Blood Diseases, LUXEMBOURG, Luxembourg

<sup>2</sup>Centre Hospitalier de Luxembourg, LUXEMBOURG, Luxembourg

### P03 Neuroendocrine neoplasms grade 3: prospective overall survival data and survival after platinum-etoposide chemotherapy within an ENETS Center of Excellence

*W. Lybaert<sup>1</sup>, A. Cuypers<sup>2</sup>, L. De Backer<sup>3</sup>, S. Stroobants<sup>3</sup>, M. Simoens<sup>4</sup>, I. Dero<sup>5</sup>, A. Driessen<sup>3</sup>, B. Op de Beeck<sup>3</sup>, W. Demey<sup>6</sup>, T. Vandamme<sup>2</sup>, M. Peeters<sup>3</sup>, On behalf of the NETwerk team<sup>7</sup>*

<sup>1</sup>AZ Nikolaas, NETwerk, SINT-NIKLAAS, Belgium

<sup>2</sup>Antwerp University, NETwerk, ANTWERPEN, Belgium

<sup>3</sup>Antwerp University Hospital, NETwerk, EDEGEM, Belgium

<sup>4</sup>ZNA Jan Plafijn, NETwerk, MERKSEM, Belgium

<sup>5</sup>Sint-Augustinus Ziekenhuis, GZA, NETwerk, WILRIJK, Belgium

<sup>6</sup>KLINA, NETwerk, BRASSCHAAT, Belgium

<sup>7</sup>NETwerk, EDEGEM, Belgium

**Po4 FGF- R inhibition, a biomarker driven alternative in second line metastatic urothelial cancer**

*Daan De Maeseneer, Nora Sundahl, Valerie Fonteyne, Jeroen Van Besien, Karel Decaestecker, Sylvie Rottey  
UZ Gent, GENT, Belgium*

**Po5 The safety of anti-PD1 therapy in a case of paraneoplastic immune disease: a case report**

*Laila Belcaid, Maroun Sadek, Youssef Jounblat, Sandrine Aspeslagh, Marie Vercauysen  
<sup>1</sup>Institute Jules Bordet, BRUXELLES, Belgium*

**Po6 Renal cell carcinoma with TFE3 rearrangement at Xp11.2**

*Enora Vauléon, Maroun SADEK, Ahmad AWADA  
Jules Bordet, BRUSSELS, Belgium*

**Po7 Incidence and prognosis of biliary tract and gallbladder cancers in an academic hospital**

*Quentin Gilliaux, Laurence Faugeras, Jean-Paul Martinet, Thierry De Ronde, Claude Bertrand, Alexandra Dili,  
Monique Delos, Jacques Jamart, Lionel D'Hondt  
Université Catholique de Louvain, CHU UCL Namur, Site Godinne, YVOIR, Belgium*

**Po8 Hemophagocytic lymphohistiocytosis, an unusual initial presentation of a gastric adenocarcinoma with an unusual exclusive bone marrow metastasis**

*Youssef Jounblat<sup>1</sup>, Georges El Hachem<sup>2</sup>  
<sup>1</sup>Lebanese University, BEIRUT, Lebanon  
<sup>2</sup>Saint George Hospital University Medical Center, BEIRUT, Lebanon*

**Po9 A case report of a psoriasis flare-up during treatment with an immune-checkpoint inhibitor**

*Boudewijn Dullens, Jeroen Mebis  
Virga Jessa Hasselt, HASSELT, Belgium*

**P11 Case report of myopericarditis in a patient treated with an immune checkpoint inhibitor**

*Lotte Segers, Jeroen Mebis  
Jessa Ziekenhuis, HASSELT, Belgium*

**P12 Successful and durable disease control after treatment by peptide receptor radionuclide therapy in a patient with disseminated insulinoma: a case report.**

*Laila Belcaid, Maroun Sadek, Youssef Jounblat, Ioannis Karfis  
Institute Jules Bordet, BRUXELLES, Belgium*

**P13 LONG-TERM CLINICAL FOLLOW-UP OF BREAST CANCER PATIENTS TREATED WITH PHOTOBIO-MODULATION THERAPY TO PREVENT ACUTE RADIODERMATITIS (TRANS-DERMIS TRIAL): PRELIMINARY RESULTS**

*Jolien Robijns<sup>1</sup>, Sofie Puts<sup>1</sup>, Joy Lodewijckx<sup>1</sup>, Sandrine Censabella<sup>2</sup>, Stefan Claes<sup>2</sup>, Luc Pannekoek<sup>2</sup>,  
Lore Bussé<sup>1</sup>, Iris Kaminski<sup>1</sup>, Dora Colson<sup>1</sup>, Annelies Maes<sup>2</sup>, Leen Noé<sup>2</sup>, Marc Brosens<sup>2</sup>, Paul Bulens<sup>2</sup>,  
An Timmermans<sup>2</sup>, Ivo Lambrichts<sup>1</sup>, Veerle Somers<sup>1</sup>, Jeroen Mebis<sup>2</sup>  
<sup>1</sup>Hasselt University, HASSELT, Belgium  
<sup>2</sup>Jessa Hospital, HASSELT, Belgium*

**P14 Unexpected timed presentation of dermatomyositis associated with advanced ovarian cancer**

*Mohammad Fadi Pirbuccus, Thierry Pepersack, Carole Nagant, Gauthier Rémiche, Myriam Roos, Hazim  
Kadhim Frédéric Vandergheynst, Michèle Courreau, Lissandra Dal Lago, Ahmad Awada, Jean Klasterky,  
Joseph Kerger  
Institut Jules Bordet, BRUSSELS, Belgium*

**P15 Hemangiopericytoma with liver metastasis treated by Selective Internal Radiation Therapy complicated by a gastric ulcer requiring gastrectomy: a case report.**

*Laila Belcaid, Maroun Sadek, Gabriel Liberale, Ahmad Awada  
Institute Jules Bordet, BRUXELLES, Belgium*

**P16 New hopes generated by Next-generation Sequencing of rare tumors: a case of a metaplastic carcinoma of the breast with mesenchymal and sacomatoid differentiation.**

*Yacine Wissam, Philippe Aftimos, Martine Piccart  
Institut Jules Bordet, BRUXELLES, Belgium*

**P17 Progression and complications in melanoma after immunotherapy and corticosteroids treatment**

*Ionela Bold, Nathalie Demaeyer, Aspasia Georgala, Roland De Wind, Bogdan Grigoriu, Joseph Kerger  
Institute Jules Bordet, BRUXELLES, Belgium*

**P18 When patients with psychiatric disorders decompensate in an oncological setting: a case report.**

*Laila Belcaid, Maroun Sadek, Youssef Jounblat, Spyros Sideris  
Institute Jules Bordet, BRUXELLES, Belgium*

**P19 Treating upper digestive bleeding may cause multiple infectious complications in a cancer patient.**

*Lorraine Tulpin<sup>1</sup>, Laura Mans<sup>1</sup>, Aspasia Georgala<sup>1</sup>, Vinciane Ledouble<sup>1</sup>, Alain Hendlisz<sup>1</sup>, Michael Vouche<sup>1</sup>,  
Daniel Blero<sup>2</sup>  
<sup>1</sup>Jules Bordet, BRUSSELS, Belgium  
<sup>2</sup>Erasmie Hospital, BRUSSELS, Belgium*

## **P20 Diagnosis of Li-Fraumeni syndrome just in time to prevent iatrogenic secondary cancer**

*Yanina Dockx<sup>1</sup>, Annabel Goossens<sup>2</sup>, Jan Declloedt<sup>3</sup>, Robin De Putter<sup>4</sup>, Nathalie Meireson<sup>5</sup>, Mieke Van De Walle<sup>1</sup>, Willem Lybaert<sup>1</sup>*

<sup>1</sup>AZ Nikolaas, SINT NIKLAAS, Belgium

<sup>2</sup>AZ Lokeren, LOKEREN, Belgium

<sup>3</sup>AZ Sint Blasius, DENDERMONDE, Belgium

<sup>4</sup>UZ Gent, GENT, Belgium

<sup>5</sup>Iridium kankernetwerk Antwerpen-Waasland, ANTWERPEN, Belgium

## **P21 One in a million**

*Sander Smeets<sup>1</sup>, Nike Van Doninck<sup>2</sup>, Lore De Ryck<sup>3</sup>, Peter Coremans<sup>2</sup>, Sigmund Keuleers<sup>2</sup>, Geert Roeyen<sup>4</sup>, Olivier D'Archambeau<sup>4</sup>, Sigrid Stroobants<sup>4</sup>, Willem Lybaert<sup>4</sup>*

<sup>1</sup>UZA, ANTWERP, Belgium

<sup>2</sup>AZ Nikolaas, SINT-NIKLAAS, Belgium

<sup>3</sup>UZ Gent, GENT, Belgium

<sup>4</sup>NETwerk Antwerpen-Waasland, ENETS Centre of Excellence, ANTWERP, Belgium

## **P22 Immune checkpoint inhibitor and kidney transplantation.**

*Maxime Winant<sup>1</sup>, Concetta Catalano<sup>1</sup>, Sandrine Aspeslagh<sup>2</sup>, Youssef Jounblat<sup>2</sup>, Alain Lemoine<sup>1</sup>, Aspasia Georgala<sup>2</sup>*

<sup>1</sup>Erasme, BRUSSELS, Belgium

<sup>2</sup>Institut Jules Bodet, BRUSSELS, Belgium

## **P23 Repeated auto-immune hemolysis elicited by immunotherapy**

*Hanne Boen<sup>1</sup>, Tom Van den Mooter<sup>2</sup>, Annemie Rutten<sup>2</sup>, Jan Lemmens<sup>1</sup>, Luc Dirix<sup>2</sup>*

<sup>1</sup>University of Antwerp, WILRIJK, Belgium

<sup>2</sup>GZA Sint- Augustinus, WILRIJK, Belgium

## **P24 An unusual complete remission of a diffuse metastatic squamous cell cutaneous carcinoma with an EGFR-TKI**

*Maroun SADEK, Laila BELCAID, Joseph KERGER*

*Jules Bordet, BRUSSELS, Belgium*

## **P25 Urethral carcinoma. A rare disease but yet no clear guideline for treatment**

*Laila Belcaid, Maroun Sadek, Youssef Jounblat, Spyros Sideris*

*Institute Jules Bordet, BRUXELLES, Belgium*

## **P26 Autoimmune Thrombocytopenia: Another Toxicity Induced by Immunotherapy**

*Georges El Hachem<sup>1</sup>, Youssef Jounblat<sup>2</sup>*

<sup>1</sup>Saint George Hospital University Medical Center - University of Balamand, BEIRUT, Lebanon

<sup>2</sup>Lebanese University, BEIRUT, Lebanon

## **P27 From breast implants to squamous cell carcinoma**

*Maroun SADEK, Laila Belcaid, Andrea Gombos, Ahmad Awada*

*Jules Bordet, BRUSSELS, Belgium*

## **P28 A rare tumor of the parotid gland**

*Maroun SADEK, Laila BELCAID, Ahmad Awada*

*Jules Bordet, BRUSSELS, Belgium*

## **P29 Genomic profiling of patients with metastatic castration-resistant prostate cancer (mCRPC) for the evaluation of rucaparib: next-generation sequencing (NGS) of tumour tissue and cell-free DNA (cfDNA)**

*Brieuc Sautois<sup>1</sup>, Dirk Schrijvers<sup>2</sup>, Geoffrey Matus<sup>3</sup>, Siska Van Bruwaene<sup>4</sup>, Sylvie Rottey<sup>5</sup>, Ray McDermott<sup>6</sup>, Josep Maria Piulats<sup>7</sup>, Jeremy D. Shapiro<sup>8</sup>, M. Neil Reaume<sup>9</sup>, Peter Ostler<sup>10</sup>, Inge Mejlholm<sup>11</sup>, Ian Byard<sup>12</sup>, Arif Hussain<sup>13</sup>, John Burke<sup>14</sup>, David Morris<sup>15</sup>, David Campbell<sup>16</sup>, Teresa Mele<sup>17</sup>, Ali Benjelloun<sup>18</sup>, Dominique Spaeth<sup>19</sup>, Andrea Loehr<sup>20</sup>, Andrew D. Simmons<sup>20</sup>, Tony Golsorkhi<sup>20</sup>, Simon P. Watkins<sup>20</sup>, Simon Chowdhury<sup>21</sup>, Charles Ryan<sup>22</sup>, Wassim Abida<sup>23</sup>*

<sup>1</sup>University Hospital (CHU) of Liège, LIÈGE, Belgium

<sup>2</sup>ZNA Middelheim, ANTWERP, Belgium

<sup>3</sup>CHC Equipe de Recherche Clinique, LIÈGE, Belgium

<sup>4</sup>AZ Groeninge, KORTRIJK, Belgium

<sup>5</sup>UZ Gent, GENT, Belgium

<sup>6</sup>Adelaide and Meath Hospital (Incorporating the National Children's Hospital), DUBLIN, Ireland

<sup>7</sup>Instituto Catalan de Oncologia, BARCELONA, Spain

<sup>8</sup>Cabrini Hospital, MALVERN, Australia

<sup>9</sup>The Ottawa Hospital Cancer Centre, OTTAWA, Canada

<sup>10</sup>Mount Vernon Cancer Centre, NORTHWOOD, United Kingdom

<sup>11</sup>Vejle Sygehus, VEJLE, Denmark

<sup>12</sup>Royal Hobart Hospital, HOBART, Australia

<sup>13</sup>University of Maryland Greenebaum Cancer Center, BALTIMORE, USA

<sup>14</sup>Rocky Mountain Cancer Centers - USOR, AURORA, USA

<sup>15</sup>Urology Associates Clinical Research, NASHVILLE, USA

<sup>16</sup>University Hospital Geelong (Barwon Health), GEELONG, Australia

<sup>17</sup>Royal Marsden Hospital, LONDON, United Kingdom

<sup>18</sup>Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, MONCTON, Canada

<sup>19</sup>Centre d'Oncologie de Gentilly, NANCY, France

<sup>20</sup>Clovis Oncology, Inc., BOULDER, USA

<sup>21</sup>Guy's Hospital and Sarah Cannon Research Institute, LONDON, United Kingdom

<sup>22</sup>University of Minnesota, MINNEAPOLIS, USA

<sup>23</sup>Memorial Sloan Kettering Cancer Center, NEW YORK, USA